-+ 0.00%
-+ 0.00%
-+ 0.00%

Akari Therapeutics enters research collaboration with WhiteHawk Therapeutics on dual-payload ADCs

PUBT·08/04/2026 12:50:20
Listen to the news
Akari Therapeutics enters research collaboration with WhiteHawk Therapeutics on dual-payload ADCs
  • Akari Therapeutics entered a strategic research collaboration with WhiteHawk Therapeutics to evaluate a dual-payload antibody-drug conjugate strategy.
  • The work combines Akari’s PH1 spliceosome-modulating payload with WhiteHawk’s TOP1 inhibitor ADC platform to test complementary mechanisms.
  • Akari also reiterated plans to advance its lead TROP2-targeting ADC, AKTX-101, toward a Phase 1 clinical trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040850PRIMZONEFULLFEED9802930) on August 04, 2026, and is solely responsible for the information contained therein.